Y101D / YZY Biopharma - LARVOL DELTA

A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=50 | Completed | Sponsor: Wuhan YZY Biopharma Co., Ltd. | Active, not recruiting ➔ Completed | N=126 ➔ 50

Enrollment change • Trial completion • Solid Tumor

A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - P1/2 | N=71 | Active, not recruiting | Sponsor: Wuhan YZY Biopharma Co., Ltd. | Trial completion date: Dec 2024 ➔ Oct 2025 | Trial primary completion date: Jul 2024 ➔ Mar 2025

Trial completion date • Trial primary completion date • Oncology • Pancreatic Cancer • Solid Tumor • CA 19-9

A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - P1/2 | N=71 | Active, not recruiting | Sponsor: Wuhan YZY Biopharma Co., Ltd.

Combination therapy • Metastases • New P1/2 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=126 | Active, not recruiting | Sponsor: Wuhan YZY Biopharma Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Aug 2023 ➔ Aug 2024 | Trial primary completion date: Aug 2022 ➔ Mar 2024

Enrollment closed • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Phase 1 Study of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors (clinicaltrials.gov) - P1; N=126; Recruiting; Sponsor: Wuhan YZY Biopharma Co., Ltd.

Clinical • New P1 trial • Oncology • Solid Tumor